TY  - JOUR
AU  - Trigg, Ricky M
AU  - Lee, Liam C
AU  - Prokoph, Nina
AU  - Jahangiri, Leila
AU  - Reynolds, C Patrick
AU  - Amos Burke, G A
AU  - Probst, Nicola A
AU  - Han, Miaojun
AU  - Matthews, Jamie D
AU  - Lim, Hong Kai
AU  - Manners, Eleanor
AU  - Martinez, Sonia
AU  - Pastor Fernandez, Joaquin
AU  - Blanco-Aparicio, Carmen
AU  - Merkel, Olaf
AU  - Garces de Los Fayos Alonso, Ines
AU  - Kodajova, Petra
AU  - Tangermann, Simone
AU  - Högler, Sandra
AU  - Luo, Ji
AU  - Kenner, Lukas
AU  - Turner, Suzanne D
PY  - 2019
DO  - 10.1038/s41467-019-13315-x
SN  - 2041-1723
UR  - http://hdl.handle.net/20.500.12105/9298
AB  - Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling. To proactively identify resistance...
LA  - eng
PB  - Nature Publishing Group
KW  - Anaplastic Lymphoma Kinase
KW  - Animals
KW  - Apoptosis
KW  - Biphenyl Compounds
KW  - Cell Line, Tumor
KW  - Drug Resistance, Neoplasm
KW  - Gene Knockdown Techniques
KW  - Humans
KW  - Mice
KW  - N-Myc Proto-Oncogene Protein
KW  - Neuroblastoma
KW  - Organophosphorus Compounds
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins c-pim-1
KW  - Pyrimidines
KW  - Sulfones
KW  - Thiazolidines
KW  - Xenograft Model Antitumor Assays
TI  - The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
TY  - journal article
ER  -